Table 2.
Patient characteristics, details of interventions, outcomes, and methodological quality score for trials included in our meta-analyses
| Trial | Meta-analysis | Setting | No of patients | Mean age (years) | Intervention | Control | Outcomes | Methodological quality score* |
|---|---|---|---|---|---|---|---|---|
| Ruiz-Santana et al, 199111 | A | ICU | 49 | R=39 P=39 | Ranitidine 50 mg iv every 6 hours | Placebo | See table 3 | 7 |
| Apte et al, 199212 | A | Medical ICU | 34 | R=27† P=26† | Ranitidine 50 mg iv every 6 hours | Placebo | See table 3 | 6 |
| Metz et al, 199313 | A | ICU | 167‡ | R=35.4 P=32.5 | Ranitidine 6.25 mg/hr by continuous infusion | Placebo | See table 3 | 8 |
| Burgess et al, 199514 | A | Surgical ICU | 34 | R=38.4 P=34.5 | Ranitidine 6.25 mg/hr by continuous infusion | Placebo | See table 3 | 6 |
| Hanisch et al, 199815 | A | Surgical ICU | 114 | R=55 P=58 | Ranitidine 50 mg tid iv | Placebo | See table 3 | 6 |
| Ruiz-Santana et al, 199111 | B | ICU | 54 | S=37 P=39 | Sucralfate 1 g by nasogastric tube every 4 hours | Placebo | See table 4 | 7 |
| Apte et al, 199212 | C | Medical ICU | 34 | R=27† P=26† | Ranitidine 50 mg iv every 6 hours | Placebo | See table 5 | 5 |
| Metz et al, 199313 | C | ICU | 163‡ | R=35.4 P=32.5 | Ranitidine 6.25 mg/hr by continuous infusion | Placebo | See table 5 | 7 |
| Hanisch et al, 199815 | C | Surgical ICU | 114 | R=55 P=58 | Ranitidine 50 mg tid iv | Placebo | See table 5 | 6 |
| Ben-Menachem et al, 199418 | D | Medical ICU | 200 | S=60.1 P=59.6 | Sucralfate 1 g given orally every 6 hours | Placebo | See table 6 | 7 |
| Eddleston et al, 199417 | D | ICU | 26 | S=47.6 P=54.9 | Sucralfate 2 g by nasogastric tube every 8 hours | Placebo | See table 6 | 5 |
| Pickworth et al, 199319 | E | Surgical ICU | 83 | R=27.3 S=26.8 | Ranitidine 50 mg iv every 6 hours | Sucralfate 1 g by nasogastric tube every 6 hours | See table 7 | 6 |
| Eddleston et al, 199120 | E | ICU | 60 | R=54.1 S=44.3 | Ranitidine 50 mg iv every 6 hours | Sucralfate 1 g by nasogastric tube every 6 hours | See table 7 | 7 |
| Thomason et al, 196625 | E | Trauma, surgical, or neurosurgical ICU | 160 | R=31.0† S=27.7† | Ranitidine 6.25 mg/hr by continuous infusion | Sucralfate 1 g administered orally then 1 g by nasogastric tube every 6 hours | See table 7 | 5 |
| Prod'hom et al, 199421 | E | Medical and surgical ICU | 163 | R=52.2 S=46.4 | Ranitidine 6.25 mg/hr by continuous infusion | Sucralfate 1 g by nasogastric tube every 4 hours | See table 7 | 6 |
| O'Keefe et al, 199826§ | E | ICU | 96 | R=34.3 S=34.2 | Ranitidine 0.25 mg/kg/hr, after loading dose of 0.5 mg/kg | Sucralfate 1 g by nasogastric tube every 6 hours | See table 7 | 6 |
| Laggner et al, 198922 | E | ICU | 32 | R=60 S=47 | Ranitidine 50 mg iv every 4 hours | Sucralfate 1 g by gastric tube every 4 hours | See table 7 | 5 |
| Cook et al, 19983 | E | ICU | 1200 | R=58.8 S=58.7 | Ranitidine 50 mg iv every 8 hours | Sucralfate 1 g by nasogastric tube every 6 hours | See table 7 | 9 |
| Mustafa et al, 199523 | E | ICU | 31 | Not reported | Ranitidine 100 mg iv every 8 hours | Sucralfate 2 g by nasogastric tube every 6 hours | See table 7 | 1 |
*
In assessment of blinding we assigned score of 1 to single blind studies in which outcome assessor was blind and both caregiver and patient were unblind.
†
Median.
‡
Population studied in effectiveness analysis (n=167) differed from that included in analysis on pneumonia (n=163) because four patients had pneumonia at baseline.
§
Results of this clinical trial have in part been reported previously.24
R=ranitidine; P=placebo; S=sucralfate; ICU=intensive care unit.